DataExpo GAKG DeepReport Navigation

Copyright©2015-2024 Acemap, Inc. Shanghai Jiao Tong University. All rights reserved.

沪ICP备18028330号

GM

Guillermo Montalban‐Bravo

The University of Texas MD Anderson Cancer Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Guillermo García-Manero

The University of Texas MD Anderson Cancer Center

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Tapan M. Kadia

The University of Texas MD Anderson Cancer Center

Farhad Ravandi

The University of Texas MD Anderson Cancer Center

Elias Jabbour

The University of Texas MD Anderson Cancer Center

Courtney D. DiNardo

The University of Texas MD Anderson Cancer Center

Koji Sasaki

The University of Texas MD Anderson Cancer Center

Nicholas J. Short

The University of Texas MD Anderson Cancer Center

Gautam Borthakur

The University of Texas MD Anderson Cancer Center

Kelly S. Chien

The University of Texas MD Anderson Cancer Center

Cooperative Institutions

The University of Texas MD Anderson Cancer Center

The University of Texas Health Science Center at Houston

Moffitt Cancer Center

Harvard University

Istituti di Ricovero e Cura a Carattere Scientifico

Baylor College of Medicine

Massachusetts General Hospital

Scripps MD Anderson Cancer Center

Dana-Farber Cancer Institute

Leukemia Research Foundation

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

The influence of preoperative overnight fasting under insulin resistance in patients to undergo a videolaparoscopic cholecystectomy

A. Martinez Immaculata Xess Indulis Vanags Myung Hee Yoon Pernille Vaabengaard

Preoperative Fasting

Cite

Citations (0)

Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia

Curtis A. Lachowiez Courtney D. DiNardo Koichi Takahashi Sanam Loghavi Lianchun Xiao

Flag (linear algebra)

Idarubicin

Venetoclax

Regimen

Induction chemotherapy

Decitabine

Chemotherapy regimen

10.1182/blood-2021-150457

Cite

Citations (6)

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Jayastu Senapati Emmanuel Almanza Tapan M. Kadia Guillermo Montalban‐Bravo Stefan Faderl

Gemtuzumab ozogamicin

Calicheamicin

Regimen

Azacitidine

Decitabine

10.1182/blood-2022-171011

Cite

Citations (1)

A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

Kiyomi Morita Hagop M. Kantarjian Guillermo Montalban‐Bravo Koji Sasaki Naval Daver

Azacitidine

10.1182/blood-2020-142003

Cite

Citations (23)

Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

Alexandre Bazinet Sai Prasad Desikan Ziyi Li Juan José Rodríguez‐Sevilla Sangeetha Venugopal

<p>Supplemental Figure 1: Overall survival and event-free survival in HMA-naïve patients by response.</p>

Venetoclax

Hypomethylating agent

10.1158/1078-0432.25515469.v1

Cite

Citations (0)

Supplemental Figure 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

Alexandre Bazinet Sai Prasad Desikan Ziyi Li Juan José Rodríguez‐Sevilla Sangeetha Venugopal

<p>Supplemental Figure 4: Effect of SCT.</p>

Venetoclax

Hypomethylating agent

10.1158/1078-0432.25515460.v1

Cite

Citations (0)

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Guillaume Richard‐Carpentier Hagop M. Kantarjian Nicholas J. Short Farhad Ravandi Alessandra Ferrajoli

Blinatumomab

Minimal Residual Disease

Regimen

Acute lymphocytic leukemia

Chemotherapy regimen

Ofatumumab

10.1182/blood-2019-129657

Cite

Citations (24)

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Àlex Bataller Alexandre Bazinet Courtney D. DiNardo Gautam Borthakur Nicholas J. Short

Decitabine

Azacitidine

Venetoclax

Hypomethylating agent

Ven

Cumulative incidence

10.1182/blood-2023-182841

Cite

Citations (0)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

Journal of Hematology & Oncology (2021)

Musa Yılmaz Mansour Alfayez Courtney D. DiNardo Gautam Borthakur Tapan M. Kadia

An amendment to this paper has been published and can be accessed via the original article.

Hematology

10.1186/s13045-020-01023-9

Cite

Citations (2)

Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

Clinical Cancer Research (2024)

Alexandre Bazinet Sai Prasad Desikan Ziyi Li Juan José Rodríguez‐Sevilla Sangeetha Venugopal

Abstract Purpose: Hypomethylating agents (HMA) combined with venetoclax are an emerging therapeutic strategy for higher-risk myelodysplastic syndromes (HR-MDS). The cytogenetic and molecular factors associated with outcomes with this combination for HR-MDS are incompletely understood. Experimental Design: We pooled patient data from 3 prospective trials evaluating HMA–venetoclax in HR-MDS to study associations between cytogenetic and molecular factors and overall response rate (ORR), overall survival (OS), and event-free survival (EFS). The Kaplan–Meier method was used to estimate time-to-event endpoints. Univariate and multivariate analyses using logistic regression (for ORR) or the Cox proportional hazards model (for OS and EFS) were used to identify associations between clinical, cytogenetic, and molecular factors and outcomes. Results: A total of 80 patients (52 HMA-naïve, 28 HMA-failure) were included. ORR was 90% in HMA-naïve and 57% in HMA-failure. Median OS was 28.2 and 8.3 months in HMA-naïve and HMA-failure, respectively. Median EFS was 17.9 and 5.5 months in HMA-naïve and HMA-failure, respectively. In addition, 24/52 (46%) of the HMA-naïve and 3/28 (11%) of the HMA-failure patients proceeded to allogeneic stem cell transplantation (SCT). Factors associated with inferior outcomes were prior HMA failure, complex cytogenetics, trisomy 8, TP53 mutations, and RAS pathway mutations. Mutations in RNA splicing, DNA methylation, and ASXL1 appeared favorable. Blast percentage was not predictive of outcomes. Conclusions: Knowledge of cytogenetic and molecular alterations may help identify which patients with HR-MDS benefit the most from venetoclax.

Venetoclax

Hypomethylating agent

Decitabine

NPM1

Azacitidine

10.1158/1078-0432.ccr-23-2860

Cite

Citations (3)

More pages